Definium Therapeutics (DFTX) CFO Roberts Buys 62,500 Shares

Definium Therapeutics CFO Brandi Roberts Acquires 62,500 Shares

Definium Therapeutics, Inc. (NasdaqGS: DFTX) saw executive transaction activity when Chief Financial Officer Brandi Roberts acquired 62,500 shares on June 22, 2026. This purchase follows other executive trades at the clinical biopharmaceutical firm, coming just days before Roberts and other company officers engaged in planned share sales later that month.

Insider Buying and Selling at Definium Therapeutics, Inc.

The June 22 transaction by CFO Brandi Roberts involved 62,500 shares acquired without an immediate reported dollar value attached to that specific acquisition date. Just three days later, on June 25, 2026, Roberts also sold 3,013 shares at an average price of $45.03, totaling $135,675.39 under a planned trading arrangement. Other executives executed sales on that same date, including Chief Commercial Officer Matthew Wiley selling 2,867 shares for $129,101.01, Chief Legal Officer Mark Sullivan parting with 13,008 shares worth $585,750.24, and Chief Medical Officer Daniel Karlin offloading 10,035 shares valued at $451,876.05. Wiley had also acquired 62,500 shares on June 22 alongside Roberts.

Stock Price Movement and Market Standing

Trading near $36.67, the company's shares have moved between a 52-week low of $9.35 and a 52-week high of $49.70. The firm operates with a market capitalization of roughly $5.28 billion and carries a beta of 2.23, reflecting wider price swings than the broader market over the past year.

Analysts Set New Price Targets

Wall Street firms maintain positive views on the biotechnology developer. On October 9, 2026, JP Morgan initiated coverage with an overweight rating and an $84.00 price target. Earlier in September, Canaccord Genuity maintained a buy rating while raising its target to $78.00 on September 15, 2026. Baird kept an outperform rating with a $79.00 target on the same day, while HC Wainwright & Co., Needham, and RBC Capital reiterated their respective buy and outperform ratings earlier in the month. Maxim Group previously maintained a buy rating with a $55.00 target on August 14, 2026, following B of A Securities initiating coverage with a buy rating and a $75.00 target on August 18, 2026.

What Definium Therapeutics Does

Definium Therapeutics is a New York-based clinical biopharmaceutical company focused on treatments for brain health disorders. Its lead candidate, DT120, is currently in phase 3 clinical trials for generalized anxiety disorder, major depressive disorder, and other conditions. Another candidate, DT402, undergoes phase 2a trials for autism spectrum disorder. The enterprise previously operated under the name Mind Medicine (MindMed) Inc. before changing its moniker in January 2026.

Looking Ahead for DFTX

Investors will follow upcoming corporate updates and the company's next earnings report scheduled for November 5, 2026, for further updates on clinical trial milestones. Insider transactions will continue to face scrutiny as officers adjust their holdings under planned arrangements.